Clinical Trial Update: Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI Failure [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Vebreltinib plus PLB1004 versus platinum-based doublet chemotherapy in EGFR-mutant, MET-positive non-small cell lung cancer after EGFR-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• PLB1004
• Vebreltinib (vebreltinib)

Snippet

Sponsor: Avistone Biotechnology Co., Ltd. | Conditions: Non-Small-Cell Lung Cancer | Phase 3 | Status: NOT_YET_RECRUITING